URGENT: Monteverde & Associates PC Invites Akari Therapeutics, Plc. Shareholders with Significant Losses To Contact The Firm Immediately - AKTX

NEW YORK, June 1, 2017

The lawsuit is based on whether Akari Therapeutics and its executives violated federal securities law by misleading investors by making false and/or misleading statements regarding the Company's business, operational and compliance policies. Specifically, Chief Executive Officer Dr. Gur Roshwalb and possibly other executives, were involved in publishing false information about the Company, including false information regarding the Phase 2 PNH trial of Coversin.

On May 11, 2017, Akari Therapeutics announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and then withdrawn on April 26, 2017 by Edison Investment Research Ltd. When the information was revealed to the public, the value of Akari Therapeutics stock dropped, causing losses to its shareholders.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/.  It is free and there is no cost or obligation to you.